IL-36 Signaling in the Tumor Microenvironment

Overview

Journal Adv Exp Med Biol

Specialties Biology
General Medicine

Date 2020 Feb 16

PMID 32060891

Citations 7

Authors

Manoj Chelvanambi

Aliyah M Weinstein

Walter J Storkus

Affiliations

Soon will be listed here.

Abstract

The ability of the immune system to prevent or control the growth of tumor cells is critically dependent on inflammatory processes that lead to the activation, expansion, and recruitment of antitumor effector cells into the tumor microenvironment (TME). These processes are orchestrated by soluble cytokines produced in tissues that alarm local immune surveillance cells (such as dendritic cells, DCs) to mobilize protective antitumor immune populations (B cells, T cells). The interleukin (IL)-36 family of pro-inflammatory cytokines plays an important role in multiple disease processes, ranging from an instigator of autoimmune psoriasis to an initiator of therapeutic immune responses against tumor cells. This chapter will focus on the biologic role of immunomodulatory IL-36 family cytokines in the cancer setting and their potential utility in the design of effective interventional therapies. (127 words).

Citing Articles

Novel therapeutic strategies targeting myeloid-derived suppressor cell immunosuppressive mechanisms for cancer treatment.

Jou E, Chaudhury N, Nasim F Explor Target Antitumor Ther. 2024; 5(1):187-207.

PMID: 38464388 PMC: 10918238. DOI: 10.37349/etat.2024.00212.

The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab.

Hawkes J, Visvanathan S, Krueger J Front Immunol. 2023; 14:1292941.

PMID: 38077370 PMC: 10703363. DOI: 10.3389/fimmu.2023.1292941.

IL-36α inhibits melanoma by inducing pro-inflammatory polarization of macrophages.

Lou X, Duan S, Li M, Yuan Y, Chen S, Wang Z Cancer Immunol Immunother. 2023; 72(9):3045-3061.

PMID: 37318520 PMC: 10992341. DOI: 10.1007/s00262-023-03477-5.

IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation.

Dowling J, Nikitin P, Shen F, Shukla H, Finn J, Patel N MAbs. 2023; 15(1):2212673.

PMID: 37216961 PMC: 10208126. DOI: 10.1080/19420862.2023.2212673.

Transcriptomic and functional analyses reveal a tumour-promoting role for the IL-36 receptor in colon cancer and crosstalk between IL-36 signalling and the IL-17/ IL-23 axis.

Baker K, Brint E, Houston A Br J Cancer. 2022; 128(5):735-747.

PMID: 36482185 PMC: 9977920. DOI: 10.1038/s41416-022-02083-z.

References

Weinstein A, Giraldo N, Petitprez F, Julie C, Lacroix L, Peschaud F . Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. Cancer Immunol Immunother. 2018; 68(1):109-120. PMC: 7185158. DOI: 10.1007/s00262-018-2259-0. View

Li N, Yamasaki K, Saito R, Fukushi-Takahashi S, Shimada-Omori R, Asano M . Alarmin function of cathelicidin antimicrobial peptide LL37 through IL-36γ induction in human epidermal keratinocytes. J Immunol. 2014; 193(10):5140-8. DOI: 10.4049/jimmunol.1302574. View

Busfield S, Comrack C, Yu G, Chickering T, Smutko J, Zhou H . Identification and gene organization of three novel members of the IL-1 family on human chromosome 2. Genomics. 2000; 66(2):213-6. DOI: 10.1006/geno.2000.6184. View

Bachmann M, Scheiermann P, Hardle L, Pfeilschifter J, Muhl H . IL-36γ/IL-1F9, an innate T-bet target in myeloid cells. J Biol Chem. 2012; 287(50):41684-96. PMC: 3516718. DOI: 10.1074/jbc.M112.385443. View

Chi H, Hua K, Lin Y, Chu C, Hsieh C, Hsu Y . IL-36 Signaling Facilitates Activation of the NLRP3 Inflammasome and IL-23/IL-17 Axis in Renal Inflammation and Fibrosis. J Am Soc Nephrol. 2017; 28(7):2022-2037. PMC: 5491282. DOI: 10.1681/ASN.2016080840. View

Clancy D, Sullivan G, Moran H, Henry C, Reeves E, McElvaney N . Extracellular Neutrophil Proteases Are Efficient Regulators of IL-1, IL-33, and IL-36 Cytokine Activity but Poor Effectors of Microbial Killing. Cell Rep. 2018; 22(11):2937-2950. DOI: 10.1016/j.celrep.2018.02.062. View

Mosley B, Urdal D, Prickett K, Larsen A, Cosman D, Conlon P . The interleukin-1 receptor binds the human interleukin-1 alpha precursor but not the interleukin-1 beta precursor. J Biol Chem. 1987; 262(7):2941-4. View

Smith D, Renshaw B, Ketchem R, Kubin M, Garka K, Sims J . Four new members expand the interleukin-1 superfamily. J Biol Chem. 2000; 275(2):1169-75. DOI: 10.1074/jbc.275.2.1169. View

Jackute J, Zemaitis M, Pranys D, Sitkauskiene B, Miliauskas S, Vaitkiene S . Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer. BMC Immunol. 2018; 19(1):3. PMC: 5781310. DOI: 10.1186/s12865-018-0241-4. View

10.

Chang J, Burkett P, Borges C, Kuchroo V, Turka L, Chang C . MyD88 is essential to sustain mTOR activation necessary to promote T helper 17 cell proliferation by linking IL-1 and IL-23 signaling. Proc Natl Acad Sci U S A. 2013; 110(6):2270-5. PMC: 3568327. DOI: 10.1073/pnas.1206048110. View

11.

Chen L, Taylor J, Sabins N, Lowe D, Qu Y, You Z . Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells. Cancer Gene Ther. 2013; 20(8):469-77. PMC: 3775601. DOI: 10.1038/cgt.2013.42. View

12.

Ainscough J, Macleod T, McGonagle D, Brakefield R, Baron J, Alase A . Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36γ. Proc Natl Acad Sci U S A. 2017; 114(13):E2748-E2757. PMC: 5380102. DOI: 10.1073/pnas.1620954114. View

13.

Onoufriadis A, Simpson M, Pink A, Di Meglio P, Smith C, Pullabhatla V . Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011; 89(3):432-7. PMC: 3169817. DOI: 10.1016/j.ajhg.2011.07.022. View

14.

Milora K, Fu H, Dubaz O, Jensen L . Unprocessed Interleukin-36α Regulates Psoriasis-Like Skin Inflammation in Cooperation With Interleukin-1. J Invest Dermatol. 2015; 135(12):2992-3000. PMC: 4648684. DOI: 10.1038/jid.2015.289. View

15.

Burns K, Martinon F, Esslinger C, Pahl H, Schneider P, Bodmer J . MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem. 1998; 273(20):12203-9. DOI: 10.1074/jbc.273.20.12203. View

16.

Atkins E . Fever: the old and the new. J Infect Dis. 1984; 149(3):339-48. DOI: 10.1093/infdis/149.3.339. View

17.

Solahaye-Kahnamouii S, Farhadi F, Rahkare-Farshi M, Pakdel F, Kashefimehr A, Pouralibaba F . The effect of interleukin 36 gene therapy in the regression of tumor. Iran J Cancer Prev. 2015; 7(4):197-203. PMC: 4307102. View

18.

Vigne S, Palmer G, Martin P, Lamacchia C, Strebel D, Rodriguez E . IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. Blood. 2012; 120(17):3478-87. DOI: 10.1182/blood-2012-06-439026. View

19.

Garlanda C, Dinarello C, Mantovani A . The interleukin-1 family: back to the future. Immunity. 2013; 39(6):1003-18. PMC: 3933951. DOI: 10.1016/j.immuni.2013.11.010. View

20.

Sautes-Fridman C, Petitprez F, Calderaro J, Fridman W . Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019; 19(6):307-325. DOI: 10.1038/s41568-019-0144-6. View